GlassScriptPhysician profile
Arthur G Klose
NPI 1770681306
$2,118.79
in general payments reported to CMS, 2019-2025
26 companies · $19.04 in 2025
The $19.04 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $272 · 2021: $192 · 2022: $580 · 2023: $345 · 2024: $354 · 2025: $19.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.61 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $736.19 | 2019-2024 | Veozah, Xtandi |
| Janssen Biotech, INC. | $199.75 | 2019-2024 | Erleada |
| Abbvie INC. | $151.24 | 2020-2025 | |
| Urogen Pharma, INC. | $119.91 | 2024 | |
| Amgen INC. | $115.37 | 2019-2020 | |
| Dexcom, INC. | $96.04 | 2022 | |
| Urovant Sciences INC | $86.89 | 2022 | |
| Merck Sharp & Dohme LLC | $71.92 | 2020-2022 | |
| Boston Scientific Corporation | $65.97 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.95 | 2019 | |
| Olympus America INC. | $52.98 | 2022-2023 | Oes Cystonephrofiberscope |
| Zyla Life Sciences, INC. | $52.49 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $51.40 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $50.76 | 2020-2022 | |
| Lilly USA, LLC | $33.04 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $25.97 | 2019 | |
| Baxter Healthcare | $25.91 | 2024 | Tisseel |
| Arbor Pharmaceuticals, INC. | $23.08 | 2019-2020 | |
| Cequr Corporation | $17.22 | 2024 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $14.36 | 2020 | |
| Eisai INC. | $14.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.10 | 2020 | |
| Amarin Pharma, INC. | $12.01 | 2021 | |
| Myovant Sciences INC. | $11.43 | 2021 | |
| Novo Nordisk INC | $11.02 | 2019 | |
| Radius Health, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Klose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.